Aseline by age group at enrollment, while Figure 1b shows HSV-2 incidence during follow-up by age group at enrollment. HSV-2, herpes simplex virus type 2. doi:10.1371/journal.pone.0091513.gDiscussionIn this analysis of participants in the iPrEx trial of daily oral FTC/TDF PrEP, we found no association between FTC/TDF and incidence of HSV-2 infection, even after accounting for actual use of FTC/TDF
N of cRAI in the past three months being reported more frequently in the placebo arm (P = 0.01). Of the 1,383 participants who tested seronegative for HSV-2 at baseline, 36 (2.6 ) did not contribute person-time to incidence analyses because they were retrospectively found to be HIVinfected at baseline, tested seropositive for HSV-2 at the enrollment visit subsequent to screening, or were lost to f
N, transgender identity, alcohol use, or sexual behaviors.FTC/TDF and ulcer occurrenceA total of 1,019 participants tested seropositive for HSV-2 at baseline or during follow-up; of those, 22 (2.2 ) tested seropositive for HSV-2 after HIV seroconversion. Among the remaining 997,Daily Oral FTC/TDF PrEP and HSV-2 among MSMTable 1. Characteristics of participants testing HSV-2 seronegative at baselin
N, transgender identity, alcohol use, or sexual behaviors.FTC/TDF and ulcer occurrenceA total of 1,019 participants tested seropositive for HSV-2 at baseline or during follow-up; of those, 22 (2.2 ) tested seropositive for HSV-2 after HIV seroconversion. Among the remaining 997,Daily Oral FTC/TDF PrEP and HSV-2 among MSMTable 1. Characteristics of participants testing HSV-2 seronegative at baselin
Lcer was identified, and 5.6 had 1 STI examination during which a groin ulcer was identified after HIV seroconversion, and thus after stopping study drug. The proportions with each type of ulcer did not differ between participants in the FTC/TDF arm and participants in the placebo arm. Finally, the iPrEx protocol did not use the HSV-2 test manufacturer's suggested cutoffs for indeterminate (IR
Lcer was identified, and 5.6 had 1 STI examination during which a groin ulcer was identified after HIV seroconversion, and thus after stopping study drug. The proportions with each type of ulcer did not differ between participants in the FTC/TDF arm and participants in the placebo arm. Finally, the iPrEx protocol did not use the HSV-2 test manufacturer's suggested cutoffs for indeterminate (IR
N, transgender identity, alcohol use, or sexual behaviors.FTC/TDF and ulcer occurrenceA total of 1,019 participants tested seropositive for HSV-2 at baseline or during follow-up; of those, 22 (2.2 ) tested seropositive for HSV-2 after HIV seroconversion. Among the remaining 997,Daily Oral FTC/TDF PrEP and HSV-2 among MSMTable 1. Characteristics of participants testing HSV-2 seronegative at baselin
No differences by randomization group in the proportion of participants with 1 STI examination during which a perianal ulcer (FTC/TDF 3.5 vs. placebo 4.7 , P = 0.37) or groin ulcer (FTC/TDF 2.5 vs. placebo 1.9 , P = 0.51) was identified; results were similar after excluding participants with a positive syphilis rapid plasma reagin test at the same visit. However, symptoms that prompted STI exam